ClinicalTrials.gg

Program

FLT3 Inhibitor XY0206

Also written as “XY0206” and “[14C]XY0206”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Shijiazhuang Yiling Pharmaceutical.

Furthest: phase 3, since May 17, 20235 company-led studies, 3 open or runningNext primary completion: Jul 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shijiazhuang Yiling Pharmaceutical53 open or runningphase 3since May 17, 2023Aug 8, 2018Jul 1, 2027phase 3 · NCT05876832

Also a collaborator on its studies: Proswell Medical and Tigermed Consulting.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2018First study: phase 1 study in Advanced or Metastatic Solid TumoursFirst studyNCT03658070 · 34 enrolled · China
  2. Jul 1, 2020Phase 1 study in Leukemia, Myeloid, AcuteNCT04471064 · 60 planned · China
  3. May 17, 2023Phase 3 study in Acute Myeloid Leukemia With FLT3/ITD MutationNCT05876832 · 312 planned
  4. Feb 7, 2025Phase 1 study in Metabolism of Radioactive SubstancesNCT06823232 · 6 enrolled · China
  5. Aug 26, 2025Phase 1 study in Acute Myeloid Leukemia With FLT3/ITD MutationNCT07162116 · 45 planned · China

Ahead

  1. Jul 1, 2027Primary completion: phase 3 study in Acute Myeloid Leukemia With FLT3/ITD MutationNCT05876832

TargetBeta

FLT3 →read by rule
“A selective inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) ”NCIt, by rule

Other programs on FLT3

ProgramCompanyFurthest phaseStudies
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
quizartinibruleDaiichi Sankyophase 322
gilteritinibruleAstellas Pharmaphase 320
pacritinibruleSwedish Orphan Biovitrumphase 318
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37
flonoltinibruleChengdu Zenitar Biomedical Technologyphase 37
nefextinibrulemaxinovel-pty-ltdphase 29
Anti-FLT3/CD3 Bispecific Antibody CLN-049rulecullinan-therapeutics-incphase 22
flonoltinib maleateruleChengdu Zenitar Biomedical Technologyphase 22
HPB-092rulehangzhou-polymed-biopharmaceuticals-incphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07162116Acute Myeloid Leukemia With FLT3/ITD Mutation · China1RecruitingDec 1, 202545
NCT06823232Metabolism of Radioactive Substances · China1CompletedDec 5, 20246
NCT05876832Acute Myeloid Leukemia With FLT3/ITD Mutation3Not yet recruitingJul 1, 2027312
NCT04471064Leukemia, Myeloid, Acute · China1RecruitingFeb 202460
NCT03658070Advanced or Metastatic Solid Tumours · China1UNKNOWNDec 202034

How it is read

Names in the registry

  • “XY0206”, 4 entries
  • “[14C]XY0206”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.